Differential regulation of breast cancer bone metastasis by PARP1 and PARP2.

and dual inhibitors, such as olaparib, have been recently FDA approved for the treatment of advanced breast and ovarian cancers. However, their effects on bone mass and bone metastasis are unknown. Here we show that olaparib increases breast cancer bone metastasis through but not specifically in the myeloid lineage, but not in the cancer cells. Olaparib treatment or deletion promotes osteoclast differentiation and bone loss. Intriguingly, myeloid deletion of Pduanyu372, but not Pduanyu371, increases the population of immature myeloid cells in bone marrow, and impairs the expression of chemokines such as CCL3 through enhancing the transcriptional repression by β-catenin. Compromised CCL3 production in turn creates an immune-suppressive milieu by altering T cell subpopulations. Our findings warrant careful examination of current inhibitors on bone metastasis and bone loss, and suggest cotreatment with CCL3, β-catenin inhibitors, anti-RANKL or bisphosphonates as potential combination therapy for Pduanyu37 inhibitors.

KEYWORDS: {{ getKeywords(articleDetailText.words) }}